Risdiplam is the one orally administered drug approved to the treatment of SMA. It was FDA accepted in 2020 to be used in clients two months of age and older, and it functions as an SMN2 gene splicing modifier leading to larger levels of SMN protein. Oral administration is an https://stevei295brf0.vblogetin.com/profile